Securities code: 002411 securities abbreviation: Yanan Bicon Pharmaceutical Listed Company(002411) Announcement No.: 2022-008 Yanan Bicon Pharmaceutical Listed Company(002411)
Stock trading abnormal fluctuation announcement
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Abnormal fluctuation of stock trading
Yanan Bicon Pharmaceutical Listed Company(002411) (hereinafter referred to as "the company" or "the company", securities abbreviation: Yanan Bicon Pharmaceutical Listed Company(002411) , securities code: 002411) the stock trading price has fallen more than 20% from the closing price for two consecutive trading days (January 14, 2022 and January 17, 2022). According to the relevant regulations of Shenzhen Stock Exchange, it belongs to the situation of abnormal fluctuation of stock trading.
2、 Description of the company's concern and verification
In view of the abnormal fluctuation of the company's stock trading, the company checked the relevant matters and asked the controlling shareholder, actual controller and the company's management. The relevant information is described as follows:
1. On December 31, 2021, the company received the decision on administrative supervision measures issued by Shaanxi regulatory bureau of China Securities Regulatory Commission. The company has the situation that the controlling shareholders and their related parties occupy the company's funds for non-profit purposes and provide external guarantees in violation of regulations. On January 4, 2022, the company received the letter of concern on Yanan Bicon Pharmaceutical Listed Company(002411) issued by the second Department of management of listed companies of Shenzhen Stock Exchange (company department concern letter [2022] No. 1) (hereinafter referred to as "concern letter"), requiring the company to make a written explanation on relevant matters before January 13, 2022. On January 14, 2022, the company disclosed the announcement on delaying the reply to the letter of concern of Shenzhen Stock Exchange and the suggestive announcement on the possible implementation of other risk warnings on the company's shares (Announcement No.: 2022-002, 2022-003) on the designated information disclosure media. In view of the many issues involved in the letter of concern and the heavy workload, the relevant issues need further verification and improvement, supplemented with corresponding information, and currently affected by New Coronavirus pneumonia in Xi'an, which brings certain difficulties to the recovery work. In order to effectively and steadily reply to the letter of concern and ensure the authenticity, accuracy and completeness of the reply, after careful study, the company has applied to the management department of listed companies of Shenzhen stock exchange for an extension to reply to the letter of concern before January 27, 2022. 2. Except for the statutory disclosure media announcement or the public media reprinting the above matters disclosed by the company, the company has not found any other unpublished material information reported by the public media that may or has had a great impact on the stock trading price of the company.
3. The company did not find that the information disclosed in the previous period needed to be corrected and supplemented.
4. Recently, the company's production and operation are normal, and the internal and external business environment has not changed significantly.
5. Upon inquiry, the company, the controlling shareholder and the actual controller have no major events that should be disclosed but not disclosed about the company or major events in the planning stage.
6. As the controlling shareholder Xinyi Bikang new pharmaceutical industry complex Investment Co., Ltd. has entered bankruptcy reorganization, according to Article 19 of the enterprise bankruptcy law of the people's Republic of China, after the people's court accepts the bankruptcy application, the preservation measures related to the debtor's property shall be lifted and the execution procedure shall be suspended. Yan'an intermediate people's Court of Shaanxi Province has ordered Xinyi Bikang All shares of the company held by Shaanxi Beidu New Material Technology Co., Ltd. and Li zongsong shall be subject to property preservation measures, and all shares and corresponding interests under their names shall be frozen. Therefore, during the period of abnormal stock price fluctuation, Xinyi Bikang and its concerted action did not buy or sell the company's shares, nor did they encounter forced closing positions through centralized bidding, did they take the initiative to reduce their holdings through centralized bidding transactions, and there is no plan to take the initiative to reduce their holdings through centralized bidding transactions in the future.
7. No other matters that should be disclosed were found in the process of attention and verification.
3、 Whether there is a description of information that should be disclosed but not disclosed
The board of directors of the company confirms that at present, the company has no undisclosed matters or planning, negotiation, intention, agreement, etc. related to the matters that should be disclosed in accordance with the stock listing rules of Shenzhen Stock Exchange and other relevant provisions; The board of directors has not been informed that the company has undisclosed information that should be disclosed in accordance with the stock listing rules of Shenzhen Stock Exchange and other relevant provisions and has a great impact on the stock trading price of the company; There is no need to correct or supplement the information disclosed by the company in the early stage.
4、 Risk tips deemed necessary by the company
1. Through self-examination, the board of directors of the company believes that the company does not violate fair information disclosure.
2. Securities times, China Securities News, Shanghai Securities News, securities daily and cninfo（ http://www.cn.info.com.cn. ）As the information disclosure media designated by the company, all information of the company shall be subject to the official announcement published by the company in the above designated media. Please invest rationally and pay attention to investment risks.
It is hereby announced.
Yanan Bicon Pharmaceutical Listed Company(002411) board of directors
January 18, 2002
